Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3903640 | 0.89 | CYP1A2 (0.74) | CYP1A2KMT2AFFAR1ALDH1A1GAA | |
| SCHEMBL13790821 | 0.88 | CYP1A2 (0.54) | CYP1A2KMT2AFFAR1ALDH1A1GAA | |
| SCHEMBL13178572 | 0.82 | SLC7A5 (0.50) | CYP1A2FFAR1ALDH1A1GAAKDM4E | |
| SCHEMBL11624631 | 0.80 | SIRT2 (0.47) | KMT2AFFAR1GAARAB9A | |
| SCHEMBL4396609 | 0.80 | SMPD1 (0.55) | CYP1A2FFAR1SMN1; SMN2 | |
| SCHEMBL4396452 | 0.78 | CYP1A2 (0.52) | CYP1A2KMT2AFFAR1ALDH1A1GAA | |
| SCHEMBL4396667 | 0.78 | CYP1A2 (0.54) | CYP1A2KMT2AFFAR1ALDH1A1GAA | |
| SCHEMBL4400261 | 0.77 | ROCK2 (0.49) | CYP1A2KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL4396155 | 0.77 | CYP1A2 (0.48) | CYP1A2KMT2AFFAR1SMN1; SMN2 | |
| SCHEMBL4402844 | 0.77 | CYP1A2 (0.51) | CYP1A2KMT2AFFAR1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1067109-B1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7211591-B2 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7211591-B2 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7211591-B2 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7037914-B2 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20050250824-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-11-10 | — | — | US | disclosed |
| US-20030153579-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2003-08-14 | — | — | US | disclosed |
| US-6506757-B1 | A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative, is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-01-14 | — | — | US | disclosed |
| EP-1067109-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153579-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | PPARA, PPARG, PPARD | CYP1A2 316/4885KMT2A 1654/4885FFAR1 9/4885 |
| US-20050250824-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | PPARA, PPARG, PPARD | CYP1A2 322/4885KMT2A 1405/4885FFAR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.